tokens: A Phase II trial of cisplatin plus WR-2721 ( amifostine ) for metastatic breast carcinoma : an Eastern Cooperative Oncology Group Study ( E8188 ). BACKGROUND : Cisplatin has minimal antitumor activity when used as second - or third - line treatment of metastatic breast carcinoma .